Journal of Drug Metabolism & Toxicology
Open Access

Abstract

Effect of CB1-Antagonist (AM251) on Metabolic Syndrome (Prophylactic and Therapeutic)

Ahmed Mohammed Taha, Elsayed Mohammed Tayee, Dalia Ali Gaber, Deaa Fekri Morsi and Abdelbaset Taher Abdelhalim

The present study was designed to investigate the possible prophylactic and therapeutic effect of cannabinoid receptors type1 (CB1) antagonist (AM251) on fructose-induced metabolic syndrome in rats, through administration of high fructose diet for 12 weeks. Prophylactic treatment by CB1-antagonist (AM251) significantly returned triglyceride, inflammatory, oxidative stress parameters and liver enzymes to the normal values while it significantly improved blood pressure, glucose, insulin, and IR and lipid profile but not significantly returned to the normal values. Interestingly, it significantly decreased body weight to values less than corresponding normal group. Histopathological findings confirmed that CB1-antagonist (AM251) in both prophylactic and therapeutic group improved histopathological changes of the liver and aorta induced by high fructose (60%) diet, with no drug had the upper hand of improvement of these histopathological changes.